| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | President & CEO | Interim CEO
2 companies
Anthony G. Quinn last filed a Form 4 in June 2025, as President & CEO at SYRE. The filings on record cover 2 companies. From April 2016 to January 2025, the filings on record show 13 open-market purchases and 0 sales. Anthony G. Quinn's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Anthony G. Quinn a below-average insider score of 37/100, based on 9 past trades. Over a 12-month horizon, 11.1% of those trades were profitable, with an average 12-month return of -64.5%.
At the last filing, the largest reported position was 550,540 shares of SYRE. Net of sales, the SYRE filings show accumulation of 558,992 shares.
Shares as reported in the last Form 4 for each company; the most recent is from June 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 8, 2017 | SYRE Spyre Therapeutics, Inc. | Interim CEO | Buy | 8,288 | $4.96 | $41,078.38 | +30.6% | |
| Dec 5, 2017 | SYRE Spyre Therapeutics, Inc. | Director | Buy | 17,121 | $4.86 | $83,177.50 | +171.2% | |
| Apr 12, 2016 | SYRE Spyre Therapeutics, Inc. | Director | Buy | 10,000 | $10.00 | $100,000.00 | New |